Drugs / Serdexmethylphenidate
Serdexmethylphenidate
also known as
SDX · KP-415 INNER SALT · KP415 Cl · SERDEXMETHYLPHENIDATE CHLORIDE · Serdexmethylphenidate chloride component of azstarys · Serdexmetilfenidato
Small molecule targets SLC6A2, SLC6A3 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | AZSTARYS | — | 2021-03-02 | fda.gov ↗ |
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05668754 | Dec 2022 → Feb 2024 | idiopathic hypersomnia | Zevra Therapeutics | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03292952 | Dec 2017 → May 2018 | attention deficit-hyperactivity disorder | Zevra Therapeutics | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT05721235 | Jun 2023 → Jul 2025 | attention deficit-hyperactivity disorder | Corium, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT05685732 | Mar 2023 → May 2024 | attention deficit-hyperactivity disorder | Corium, Inc. | Completed | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | serdexmethylphenidate | “KP415 (serdexmethylphenidate \[SDX\] Cl/ d-methylphenidate \[d-MPH\] HCl) oral capsule:” NCT03292952 ↗ |
| Known as | KP-415 INNER SALT | ChEMBL registry synonym — accepted as the source's own label CHEMBL4301162 ↗ |
| Known as | KP415 Cl | ChEMBL registry synonym — accepted as the source's own label CHEMBL4301162 ↗ |
| Known as | SDX | “KP415 (serdexmethylphenidate \[SDX\] Cl/ d-methylphenidate \[d-MPH\] HCl) oral capsule:” NCT03292952 ↗2“Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)” NCT05685732 ↗ “Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)” NCT05721235 ↗ |
| Known as | SERDEXMETHYLPHENIDATE CHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4301162 ↗ |
| Known as | Serdexmethylphenidate chloride component of azstarys | ChEMBL registry synonym — accepted as the source's own label CHEMBL4301162 ↗ |
| Known as | Serdexmetilfenidato | ChEMBL registry synonym — accepted as the source's own label CHEMBL4301162 ↗ |
| Action | Inhibit | “Norepinephrine transporter inhibitor” CHEMBL4301162 ↗1“Dopamine transporter inhibitor” CHEMBL4301162 ↗ |
| Modality | Small molecule | — CHEMBL4301162 ↗ |
| Route | Oral | “KP415 (serdexmethylphenidate \[SDX\] Cl/ d-methylphenidate \[d-MPH\] HCl) oral capsule:” NCT03292952 ↗ |
| Target | SLC6A2 | “Norepinephrine transporter inhibitor” CHEMBL4301162 ↗ |
| Target | SLC6A3 | “Dopamine transporter inhibitor” CHEMBL4301162 ↗ |